ASPEN trial: Long-term follow-up of zanubrutinib versus ibrutinib in patients with WM

Zanubrutinib is a covalent Bruton tyrosine kinase inhibitor that has been approved for adult patients with Waldenström Macroglobulinemia (WM) by the European Medical Agency and the U.S. Food and Drug Administration. Although the ASPEN (NCT03053440) trial did not meet its primary end point at a median follow-up of 19.4 months, zanubrutinib did exhibit encouraging safety and efficacy data compared to ibrutinib. The Lymphoma Hub is pleased to summarize the recently published long-term efficacy and safety analyses of zanubrutinib versus ibrutinib from the ASPEN trial.

Study design

This is a phase III, open-label trial of zanubrutinib versus ibrutinib in patients with WM. Full details of the study design were previously summarized on the Lymphoma Hub. Eligible patients:

• had a previous histological diagnosis of WM;
• were unsuitable for standard chemoimmunotherapy for treatment-naïve patients;
• had no previous treatment with BTK inhibitors; and
• met ≥1 criterion for treatment initiation.

Patients with 88-mutant WM were assigned to cohort 1 and those with 88-wild type WM were assigned to cohort 2. The primary endpoint was very good partial response (VGPR) plus complete response (CR) rates. Other endpoints included progression-free survival, overall survival (OS), and safety.

Results

Efficacy

In cohort 1, 99 patients were assigned to ibrutinib and 102 to zanubrutinib and in cohort 2, 28 patients were assigned to zanubrutinib. After 2-year follow-up:

• VGPR and CR rates were higher for patients who received zanubrutinib compared with ibrutinib at all time points (Figure 1).
• Median time to VGPR was shorter in patients treated with zanubrutinib compared with ibrutinib (6.7 versus 16.6 months).
• Fewer progression-free survival and OS events occurred with zanubrutinib versus ibrutinib (19.6% versus 30.3% in cohort 1). OS was comparable between cohort 1 and 2 (87.5% versus 83.9%). 

VGPR, very good partial response.
*Adapted from Dimopoulos, et al.¹

 

Safety

• Prevalence of adverse events (AEs) of interest were lower in patients treated with zanubrutinib compared with ibrutinib after 2 years, which is consistent with initial data (Figure 2A and B).
  • Although neutropenia was initially reported as more prevalent 0–12 months after treatment in patients treated with zanubrutinib, its prevalence reduced after 2 years.
• After 36 months of treatment, prevalence of infection remained lower in patients receiving zanubrutinib compared with ibrutinib.
• Treatment-emergent AEs leading to discontinuation remained lower in patients receiving zanubrutunib compared with ibrutinib (8.9% versus 20.4%).
  • The most common AEs events leading to discontinuation were cardiac disorders, infections, and infestations.
• AEs related to death occurred in eight patients, five with ibrutinib and three with zanubrutinib in cohort 1 and three in cohort 2.

*Adapted from Dimopoulos, et al.¹

 

Conclusion

Extended follow-up results show that treatment with zanubrutinib remained more efficacious than ibrutinib in the long term when comparing VGPR and CR rates. Safety and tolerability of zanubrutinib were comparable to initial results, supporting its use over ibrutinib in patients with WM, regardless of previous treatment or MYD88 mutational status.

‘The International Waldenstrom's Macroglobulinemia Foundation (IWMF) and the Lymphoma Hub are working in collaboration for patients with Waldenstrom's macroglobulinemia. This initiative aims to increase awareness of Waldenstrom's macroglobulinemia among healthcare professionals, patients, caregivers, and the patient advocacy community.

This initiative is funded by Cellectar Biosciences, BeiGene and Eli Lilly. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.’